Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deuremidevir hydrobromide - Vigonvita Life Sciences

X
Drug Profile

Deuremidevir hydrobromide - Vigonvita Life Sciences

Alternative Names: JT-001 - Junshi Biosciences; Mindevir; MINDEWEI®; VV-116

Latest Information Update: 08 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vigonvita Life Sciences
  • Developer Shanghai Junshi Biosciences; Vigonvita Life Sciences
  • Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Organic deuterium compounds; Pyrroles; Small molecules; Triazines
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered COVID 2019 infections
  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 27 Mar 2024 Vigonvita Life Sciences initiates a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (PO, suspension) (NCT06328400)
  • 20 Mar 2024 Vigonvita Life Sciences plans a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (PO, suspension) in March 2024 (NCT06328400)
  • 31 Jan 2024 Phase-II clinical trials in Respiratory syncytial virus infections (In infants) in China (PO) (NCT06206720)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top